Gout Drugs in Late-Phase Trials Might Increase Patients at Target Urate LevelJuly 9, 2024Rheumatology
Pyzchiva Receives FDA Approval as Third Ustekinumab BiosimilarJuly 2, 2024Rare DiseasesMusculoskeletal DisordersDermatologyRheumatologyGastroenterology
‘Therapeutic Continuums’ Guide Systemic Sclerosis Treatment in Updated EULAR RecommendationsJune 26, 2024Rare DiseasesDermatologyRheumatology
Sex-Related Differences Found in IgG4-Related Disease EpidemiologyJune 24, 2024Rare DiseasesPulmonologyRheumatologyNeurology
Why Do Investigational OA Drugs Need Better Trial Endpoints? Lorecivivint Serves as an ExampleJune 24, 2024Rheumatology
VEXAS Syndrome: Study Highlights Cutaneous SymptomsJune 20, 2024Rare DiseasesDermatologyRheumatologyMixed Topics
Long-Term OA, RA Symptom Improvement Seen with Plant-Based Diet, Lifestyle ChangesJune 18, 2024Rheumatology
Timing Pneumococcal Vaccination in Patients with RA Starting Methotrexate: When’s Best?June 18, 2024RheumatologyVaccines
Autoantibodies Nonspecific to Systemic Sclerosis May Play Role in ILD PredictionJune 14, 2024PulmonologyRare DiseasesRheumatology
Low Infection Risk, Apart from Herpes Zoster, Seen in Real-World JAK Inhibitor Data for RAJune 14, 2024Rheumatology
Upadacitinib Proves Successful in First JAK Inhibitor Trial for Giant Cell ArteritisJune 14, 2024Rare DiseasesRheumatology
